

Urinary retention between nerve-sparing radical hysterectomy and radical hysterectomy for cervical cancer A meta-analysis

Jing Zhou, PhD^a, Rong Zhang, MD, PhD^a, Xiaohui Tang, MD, PhD^a, Suwei Liu, PhD^a, Xiajuan Jiang, MD, PhD^{a,*} 💿

Abstract

This study intended to assess the urinary retention between nerve-sparing radical hysterectomy and radical hysterectomy in cervical cancer. Relevant studies were selected from databases of PubMed, Embase, Wanfang, and China National Knowledge Internet with the last report up to January 15, 2022. Hazard ratio (HR) and 95% confidence interval (CI) were chosen as the evaluation index. Heterogeneity was assessed using Cochran Q test and l^2 test. Subgroup analysis was conducted based on areas and cancer types (primary and metastatic cancer). A total of 8 articles (retrospective cohort studies) were selected in the meta-analysis. There were significant correlations between nerve-sparing radical hysterectomy and radical hysterectomy in related with urinary retention (HR [95% CI] = 1.78 [1.37, 2.31], P < .001) and (HR [95% CI] = 2.49 [1.43, 4.33], P = .001) of cervical cancer patients. Egger test revealed a significant publication bias (P = .014). Sensitivity analysis via omitting 1 study at each time showed that omission of any study made significant difference (P < .05), indicating reliability and good stability for the analysis. Additionally, there were significant heterogeneities in most subgroups.

Abbreviations: CI = confidence interval, HR = hazard ratio, RCT = randomized controlled trial.

Keywords: cervical cancer, meta-analysis, prognosis, urinary retention

1. Introduction

Cervical cancer is the most common gynecologic malignant tumor, extensive panhysterectomy is a radical surgery for the treatment of cervical cancer.^[1,2] The wide range of surgical resections (including the uterus, fallopian tube, the upper part of the vagina, the main ligament, and the paracolpium) and the complete dissection of the pelvic lymph nodes often brings a number of postoperative complications such as bladder dysfunction (anesthesia, urinary incontinence, and urinary retention), lymph cyst, lymphedema, ureterovaginal fistula, intestinal obstruction, wound infection, urinary tract infections, and in which bladder dysfunction is the most common. Chronic urinary retention is the accumulation of urine in the bladder that results from incomplete bladder emptying, which is the most common cause of chronic urinary retention. It is measured as the volume of urine left in the bladder after voiding, also known as postvoid residual. The 2 most common causes of chronic urinary retention and incomplete bladder emptying are bladder muscle dysfunction and bladder outlet obstruction. The latter cause is defined as a "generic term for obstruction during voiding." It is less common in women, and the prevalence data range

Chongqing Science and Technology Bureau Technology Innovation and Application Development Special Project (estc2019jscx-msxmX0223).

widely, owing to a lack of uniform definition and coexistence of storage and voiding disorders. Any process that compresses the urethra may impair urine flow and result in an obstruction; potential causes include fibroids, constipation, and, uncommonly, cancer.^[3-5]

Currently, radical resection of cervical cancer is used as the principal mean for the treatment of early cervical cancer (stage IA to IIA). During the surgical resection of cervical cancer, the pelvic autonomic nerve will be destroyed and part of the nerves that innervate the bladder will be cut off, leading to bladder contraction and sensory dysfunction, as well as urination disorders and urinary retention.^[6-8] After the urinary catheter is removed, the patient is unable to urinate successfully, which may lead to urinary tract infection and renal insufficiency in severe cases. In the process of clinical nursing, patients are usually instructed by nurses to urinary retention out intermittent clamping training about 3 days prior to catheter removal to ensure smooth urination after catheter removal. However, practice shows that intermittent pinching training alone is not effective, with unsatisfactory bladder recovery effects for patients. For this reason, new nursing methods are urgently needed to be developed in the clinic to solve the problems of

http://dx.doi.org/10.1097/MD.000000000032985

I have no commercial associations (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

^a Department of Obstetrics and Gynecology, Daping Hospital, Army Military Medical University, Chongqing, China.

^{*} Correspondence: Xiajuan Jiang, Department of Obstetrics and Gynecology, Daping Hospital, Army Military Medical University, Chongqing, China (e-mail address: ehbhyyq@126.com).

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Zhou J, Zhang R, Tang X, Liu S, Jiang X. Urinary retention between nerve-sparing radical hysterectomy and radical hysterectomy for cervical cancer: A meta-analysis. Medicine 2023;102:9(e32985).

Received: 12 November 2020 / Received in final form: 17 June 2022 / Accepted: 20 June 2022

bladder function recovery and urinary retention after radical resection of cervical cancer. $^{\left[9-11\right]}$

Although 3 prospective randomized controlled trials (RCTs) and 1 systematic review with a meta-analysis have been published up to now, they are not enough to clarify the efficacy and safety of NSRS in cervical cancer due to small numbers of enrolled patients and non-English literature that hinder extraction of relevant data. Presently, we pooled data from previously published findings and conducted a meta-analysis to combine results quantitatively. The purpose of this study was to achieve an integrative understanding of the associations between urinary retention in nerve-sparing radical hysterectomy and radical hysterectomy for cervical cancer.

2. Materials and methods

2.1. Selection strategy

Study was selected from databases of PubMed, Embase, Wanfang, and China National Knowledge Internet with the last report up to January 15, 2022. Studies for randomized controlled trials (RCTs) involving independent LNSRH and LRH as the treatment of early stage of cervical cancer based on FIGO staging. Furthermore, print-out literatures were selected by manual retrieval, and the references of reviews and included articles were further retrieved for more included studies.

2.2. Inclusion and exclusion criteria

Studies that met the following criteria were included in the present analysis: prospective or retrospective cohort study; RCT study design; related outcomes and complete data were reported. Studies were excluded if the study included only 1 surgical treatment group without a comparison design. We excluded the studies failing to report the basic study characteristics such as age, body mass index, FIGO stage. Reviews, editorials, guidelines, case reports, letters, and meeting papers were excluded.

2.3. Data extraction quality assessment

Two investigators screened articles independently according to the above inclusion and exclusion criteria. After confirming the inclusion of the analyzed articles, they independently extracted the following data according to a standardized form: the name of the first author, publication year, study area, age and sex of participants, sample size, types of patients, and intervention and complications. After completion of data extraction, the 2investigators checked each other, and the controversies were discussed and resolved.

2.4. Statistical analysis

Hazard ratio (HR) and its 95% confidence interval (CI) were chosen as the evaluation index. Heterogeneity was assessed using Cochran Q test and I^2 test.^[12] If P < .05 and/or $I^2 > 50\%$ which suggested obvious heterogeneity across studies, the random effects model would be selected to pool data. Otherwise ($P \ge .05$ and $I^2 \le$ 50%), the fixed effect model was adopted. Additionally, subgroup analysis was conducted based on areas and cancer types (primary and metastatic cancer). an I^2 of > 50% was considered to represent substantial heterogeneity, and thereby we used the random effects model using the Der Simonian and Laird method. On the other hand, the fixed effect model using the Mantel-Haenszel method was employed when I^2 was $\leq 50\%$ because it meant no heterogeneity. Egger test was used to assess whether there was publication bias. Trim and fill method, as well as sensitivity analvsis were used to evaluate the stability of results. All the statistical analyses were performed utilizing Stata11.0.

3. Results

3.1. Study selection

As shown in Figure 1, a total of 490 articles in PubMed, 324 articles in Embase, 140 articles in Wanfang, and 39 articles in




Figure 1. The detailed flow chart for literature search and study selection.

Study Area Yape of cancer. Stage n, MF Age, v Intervention Cat of follow-yru Cat of	Table 1 Information of r	eferences enr	Table 1 Information of references enrolled in this study.								
China Primary cancer, I-IV 163, 106/57 55 (15-81) Chemotherapy or SUrgery 0.132 8 1.30 (1.11, 1.52) NR Japan Metastatic cancer, NR 106, 76/30 64.5 (39-87) Hepatic resection 0.04 10 2.56 (1.42, 461) 1.73 (1.09, 2.76) 1 China Primary cancer, I-II 115, 82/33 64 (33-83) Chemotherap 0.049 5.5 5.09 (2.31, 11.56) 4.36 (2.34, 11.14) Privacian China Primary cancer, I-II 115, 82/33 64 (33-83) Chemotherapy 0.049 5.5 5.09 (2.31, 11.56) NR 61 South Korea Primary cancer, I-II 115, 82/33 64 (33-83) Chemotherapy 0.033 2.5 1.59 (1.21, 15) NR 61 South Korea Metastatic cancer, IV 148, 97/51 NR Chemotherapy 0.6712 5 1.59 (1.28, 1.99) NR 61 Japan Metastatic cancer, IV 148, 97/51 NR Chemotherapy 0.6712 5 1.56 (1.06, 3.30) NR 15 1.60 (1.06, 2.14) 81	Study	Area	Type of cancer, Stage	n, M/F	Age, yr	Intervention	Cut off value of CAR	Follow-up period, yr	OS (high vs low)	DFS (high vs low)	Adjusted factors
Japan Metastatic cancer, IN 106, 76/30 64,5 (39–87) Hepatic resection 0.04 10 2.56 (1,42,4,61) 1.73 (1.09,2.76) 1 China Primary cancer, I–II 115, 82/33 64 (33–83) Chemoradioth-era- 0.049 5.5 5.09 (2.31,11.58) 4.98 (2.34,11.14) Pri China Primary cancer, I–II 115, 82/33 64 (33–83) Chemoradioth-era- 0.049 5.5 5.09 (2.31,11.58) 4.98 (2.34,11.14) Pri South Korea Primary cancer, I–IV 627, 400/227 67 ± 12 Surgery 0.038 2.55 2.50 (1.62, 4.21) NR 61 Johan Metastatic cancer, IV 148, 97/51 NR Chemotherapy 0.6712 5 1.59 (1.28, 1.99) NR 61 Japan Metastatic cancer, IN 99, 57/42 63 (27–86) Chemotherapy 0.6712 5 1.67 (1.06, 3.30) NR 1.60 (1.05, 2.14) 51 1.60 (1.05, 2.14) 51 1.60 (1.05, 2.14) 51 1.61 (1.05, 2.14) 51 1.61 (1.05, 2.14) 51 50 (1.16, 2.30)	Asher 2011	China	Primary cancer, I-IV	163, 106/57	55 (15–81)	Chemotherapy or	0.132	œ	1.30 (1.11, 1.52)	NR	None
Chira Primary cancer, I–II 115, 82/33 64 (33–33) Chemoradioth-era- py followed by Surgery 0.049 5.5 5.09 (2.31, 11.58) 4.98 (2.34, 11.14) Prima South Korea Primary cancer, I–IV 627, 400/227 67±12 Surgery 0.038 2.5 1.59 (1.62, 421) NR 6 Chira Metastatic cancer, IV 148, 97/51 NR Chemotherapy 0.6712 5 1.59 (1.26, 1.39) NR 6 Undot Metastatic cancer, IN 94, 57/42 63 (27–86) Chemotherapy 0.6712 5 1.59 (1.26, 1.39) NR 6 Undot Metastatic cancer, IN 94, 57/42 63 (27–86) Chemotherapy 0.183 1.7 1.87 (1.06, 3.30) NR 1 Undot Primary cancer, I-II 705, 411/294 68 (26–90) Surgery 0.0271 5 1.50 (1.05, 2.14) 5 1 Undot Primary cancer, III 136, 79/57 63.5 Chemotherapy 0.112 5 NR 1.50 (1.05, 2.14) 5 China	Cho 2009	Japan	Metastatic cancer, NR	106, 76/30	64.5 (39–87)	surgery Hepatic resection	0.04	10	2.56 (1.42, 4.61)	1.73 (1.09, 2.76)	Numt
South Korea Primary cancer, I–N 627, 400/227 67 ± 12 Surgery 0.038 2.5 2.61 (1.62, 4.21) NR 6 11 Japan Metastatic cancer, IV 148, 97/51 NR Chemotherapy 0.6712 5 1.59 (1.28, 1.99) NR 1 11 Japan Metastatic cancer, IN 99, 57/42 63 (27–86) Chemotherapy 0.1633 1.7 1.87 (1.06, 3.30) NR 1 1 12 Japan Metastatic cancer, IN 99, 57/42 63 (27–86) Chemotherapy 0.183 1.7 1.87 (1.06, 3.30) NR 1 1 13 705, 411/294 68 (26–90) Surgery 0.0271 5 NR 1.50 (1.05, 2.14) 1 1 1 1.50 (1.05, 2.14) 1 1 1 1 1 1 1<0 (1.05, 2.14)	Feng 2016	China	Primary cancer, I-III	115, 82/33	64 (33–83)	Chemoradioth-era- py followed by	0.049	5.5	5.09 (2.31, 11.58)	4.98 (2.34, 11.14)	status or neoaujuvant crientounerapy Pretreatment TNM stage, Pathological TNM tage, Vascular invasion, Pretreatment CEA
China Metastatic cancer, IV 148, 97/51 NR Chemotherapy 0.6712 5 1.59 (1.28, 1.99) NR Japan Metastatic cancer, IN 99, 57/42 63 (27–86) Chemotherapy 0.183 1.7 1.87 (1.06, 3.30) NR E China Primary cancer, I-II 705, 411/294 68 (26–90) Surgery 0.0271 5 NR 1.50 (1.05, 2.14) SI China Primary cancer, III 136, 79/57 63.5 Chemotherapy 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94-10.15) China Primary cancer, III 136, 79/57 63.5 Chemotherapy 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94-10.15) China Primary cancer, III 136, 79/57 63.5 Chemotherapy 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94-10.15)	Kwon BS 2018	South Korea	Primary cancer, I–IV	627, 400/227	67±12	Surgery Surgery	0.038	2.5	2.61 (1.62, 4.21)	NR	Gender, Maximum tumor diameter, Tumor type, Pathological differentiation WBC count
Japan Metastatic cancer, NR 99, 57/42 63 (27–86) Chemotherapy 0.183 1.7 1.87 (1.06, 3.30) NR E China Primary cancer, I–III 705, 411/294 68 (26–90) Surgery 0.0271 5 NR 1.50 (1.05, 2.14) St China Primary cancer, I–III 705, 411/294 68 (26–90) Surgery 0.0271 5 NR 1.50 (1.05, 2.14) St China Primary cancer, III 136, 79/57 63.5 Chemotherapy with Colorectal 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94–10.15) China China Chemotherapy 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94–10.15)	Miao 2016	China	Metastatic cancer, IV	148, 97/51	N	Chemotherapy	0.6712	2	1.59 (1.28, 1.99)	R	Platelet count, CEA, CA19-9-00, NLR, GPS, Stage Gender, Age, Location of primary tumor, Metastasis number, Hemoglobin, Globulin,
China Primary cancer, I–III 705, 411/294 68 (26–90) Surgery 0.0271 5 NR 1.50 (1.05, 2.14) State China Primary cancer, III 136, 79/57 63.5 Chemotherapy 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94–10.15) 4 China Esection resection 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94–10.15)	Thvaramara 2011	Japan	Metastatic cancer, NR	99, 57/42	63 (27–86)	Chemotherapy	0.183	1.7	1.87 (1.06, 3.30)	NR	GPS, mGPS, NLR, PLR, MLR Detection of unresectable tumor, the number of ornans affected hy metastasis. CFA
China Primary cancer, II 136, 79/57 63.5 Chemotherapy 0.1 9 1.15 (0.91, 1.44) 4.43 (1.94–10.15) 4 china resection resection china chi	Wang 2015	China	Primary cancer, I-III	705, 411/294	68 (26–90)	Surgery	0.0271	2	N	1.50 (1.05, 2.14)	Molecular targeted therapy, Pretreatment NLR Stage, Tumor diameter, Lymphatic involvement,
4 China	Wang, 2016	China	Primary cancer, III	136, 79/57	63.5	Chemotherapy with Colorectal	0.1	0	1.15 (0.91, 1.44)	4.43 (1.94–10.15)	venous involvement, tympin node metastasis Tumor size, Vessel invasion, NLR
	Williams 2014 Zhang 2015	China				resection					

Medicine

China National Knowledge Internet were selected. Subsequent to excluding any duplicates, 869 articles remained. Then 840 irrelevant articles were removed by reviewing the titles. After reading the abstract, 16 articles were excluded. By fully reviewing the articles, 5 articles were removed. Finally, 8 articles were included in the meta-analysis.^[13-20]

3.2. Characteristics of the included studies

The characteristics of the enrolled studies are presented in Table 1. All studies were retrospective cohort studies. The areal distributions were China (2 articles) and Japan (6 articles). Quality assessment demonstrated that the quality of the included studies was relatively high (total quality scores ≥ 6) (Table 2).

3.3. Meta-analysis

Meta-analysis of urinary retention showed that there was a significant correlation between NSRH and RH treatments of cervical cancer patients (HR [95% CI] = 1.78 [1.37, 2.31], P < .001). Egger test identified a significant publication bias (P =.014). After supplementing 3 studies with trim and fill method, the pooled fixed effect model was HR (95% CI) = 1.35 (1.22, (1.49), P < .001, and the random effects model was HR (95% CI)= 1.39 (1.06, 1.83), P = .019. Sensitivity analysis revealed that after successively removing 1 study, the pooled results ranged from 1.60 (1.27, 2.00) to 1.99 (1.41, 2.82), with significant differences, which suggested that results were statistically reliable (Fig. 2).

As shown in Figure 3, meta-analysis of urinary retention revealed a significant correlation between NSRH and RH treatments of cervical cancer patients (HR [95% CI] = 2.49 [1.43, 4.33], P = .001). Significant publication bias was revealed via Egger test (P = .017). After 1 study was supplemented with trim and fill method, the pooled results were fixed effect model being HR (95% CI) = 1.80 (1.42, 2.29), P < .001 and random effects model being HR (95% CI) = 2.06 (1.20, 3.51), P = .008. Sensitivity analysis by omitting 1 study at each time showed that the pooled result ranged from 1.99 (1.22, 3.27) to 3.17 (1.50, 6.70), and omission of any study made a significant difference (P < .05), indicating statistical reliability and good stability of our results.

Table 2

Quality assessment of the included studies with Newcastle-Ottawa quality assessment scale.

Study	Representativeness of the exposed cohort	Selection of the unexposed cohort	Ascertainment of exposure	Outcome of interest not present at start of study	Control for important factor or additional factor	Outcome assessment	Follow-up long enough for outcomes to occur	Adequacy of follow-up of cohorts	
Chen YY (2017)	\$	☆	\$			☆	\$	☆	6
Haruki, K (2017)	\$	\$	\$		**	☆	\$	☆	8
lde, S (2017)	\$	\$	\$		**	☆	\$	☆	8
Ishizuka, M (2016)	\$	\$	\$		**	☆		☆	7
Ni, XF (2016)	\$	\$	\$		**	☆	\$	☆	8
Shibutani, M (2016a)	\$	☆	\$		**	☆		\$	7
Shibutani, M (2016b)	*	☆	\$		**	☆	*	\$	8
Tominaga, T (2016)	\$	☆	\$		\$	☆	\$	☆	7





Figure 2. Meta-analysis of correlation of urinary retention between NSRH and RH treatments of cervical cancer patients.



3.4. Subgroup analysis

The results of subgroup analysis are shown in Table 3. In the subgroup analysis of urinary retention, the pooled results of 2 areas and 2 types of cancer had statistical significances. There were significant heterogeneities in subgroups of China, Japan, and primary cancer. In the subgroup analysis of urinary retention, all studies were Japanese, and the pooled results of type of cancer had significant difference. Primary cancer subgroup had significant heterogeneity.

4. Discussion

In our study, we combined 8 retrospective cohort studies. Metaanalysis of urinary retention showed a significant correlation between NSRH (HR [95% CI] = 1.78 [1.37, 2.31], P < .001) and RH treatments (HR [95% CI] = 2.49 [1.43, 4.33], P = .001) of cervical cancer patients.

To the best of our knowledge, this study is the first to systematically assess the association between urinary retention and prognosis in patients with cervical cancer. The included studies had moderate methodological quality, making our analysis result reliable.^[21–23] Moreover, the stability of the results was good despite the significant publication bias. However, there were several limitations in this study that should be acknowledged. One the 1 hand, the number of included studies was small and significant between-study heterogeneity was detected. On the other hand, we performed subgroup analysis in order to reduce the heterogeneity. However, the heterogeneities between subgroups were significant as well, therefore, we cannot find the source of heterogeneity based on quantitative analysis.

NSRH was also believed to have better anorectal function in cervical cancer survivors. Although anorectal function outcomes were reported by several studies, we only found 2 relevant studies with comparable data on anorectal dysfunction.^[24,25] Due to various parameters indicating anorectal dysfunction such as constipation, defecation straining, stool incontinence and flatulence incontinence, and we chose constipation as the comparable parameter of anorectal dysfunction in this review. However, meta-analysis of anorectal dysfunction data of the 2 studies showed no significant difference between NSRH and RH, which might be due to the relatively small number of studies and participants. Since there was only 1 clinical trial with comparable data of the mean time of first flatus and first defecation, which indicated anorectal function recovery, we couldn't meta-analysis these data.^[26] In conclusion, there is a significant correlation urinary retention revealed a significant correlation between NSRH and RH treatments of cervical cancer patients Further rigorous and high-quality sample study should be designed to verify the correlation.

Author contributions

Conceptualization: Jing Zhou. Data curation: Jing Zhou, Rong Zhang. Formal analysis: Jing Zhou, Rong Zhang, Xiajuan Jiang. Funding acquisition: Rong Zhang, Xiaohui Tang. Investigation: Xiaohui Tang, Suwei Liu. Methodology: Suwei Liu. Visualization: Xiajuan Jiang. Writing – original draft: Jing Zhou, Xiajuan Jiang. Writing – review & editing: Jing Zhou, Xiajuan Jiang.

References

- Davidson T, Yakobi Y, Nayruz K, et al. Early prediction of urinary retention following radical hysterectomy by 18FFDG PET/CT imaging. Minerva Obstet Gynecol. 2021.
- [2] Meng S, Li Z, Chen L, et al. Laparoscopic radical hysterectomy for cervical cancer by pulling the round ligament without a uterine manipulator. Eur J Obstet Gynecol Reprod Biol. 2021;264:31–5.
- [3] Ceccaroni M, Roviglione G, Spagnolo E, et al. Pelvic dysfunctions and quality of life after nerve-sparing radical hysterectomy: a multicenter comparative study. Anticancer Res. 2012;32:581–8.
- [4] Chen DX. [Urinary complications following radical hysterectomy for 621 patients with cancer of uterine cervix]. Zhonghua zhong liu za zhi. 1989;11:67–70.
- [5] Chen X-J, Song Y-Y, Cai L-Z, et al. [Influence of urodynamic factors on urinary retention in patients with cervical carcinoma after radical hysterectomy]. Zhonghua Fu Chan Ke Za Zhi. 2010;45:677–81.
- [6] Derks M, van der Velden J, Frijstein MM, et al. Long-term pelvic floor function and quality of life after radical surgery for cervical cancer: a multicenter comparison between different techniques for radical hysterectomy with pelvic lymphadenectomy. Int J Gynecol Cancer. 2016;26:1538–43.
- [7] Geisler JP, Orr CJ, Khurshid N, et al. Robotically assisted laparoscopic radical hysterectomy compared with open radical hysterectomy. Int J Gynecol Cancer. 2010;20:438–42.
- [8] Komatsu H, Okawa M, Hikino K, et al. A simplified procedure of nerve-sparing radical hysterectomy. J Obstet Gynaecol Res. 2022;48:766–73.
- [9] Li F, Wu Y, Kong W, et al. Clinical efficacy of preoperative vaginal intracavitary irradiation for Stage Ib2 and IIa cervical cancer. J Cancer Res Ther. 2017;13:796–800.

- [10] Liang ZQ, Chen Y, Xu HC, et al. [Complication of laparoscopic radical hysterectomy and lymphadenectomy: an analysis of 23 cases]. Zhonghua Fu Chan Ke Za Zhi. 2005;40:438–40.
- [11] Monk BJ, Solh S, Johnson MT, et al. Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcome. Eur J Gynaecol Oncol. 1993;14:506–11.
- [12] Higgins JP, Thompson SG, Deeks J, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
- [13] Wang HF, Wang DB, Chen YH, et al. [Relief of urinary retention after radical hysterectomy for cervical cancer patients by acupressure: a randomized controlled trial]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35:425–8.
- [14] Li H, Zhou CK, Song J, et al. Curative efficacy of low frequency electrical stimulation in preventing urinary retention after cervical cancer operation. World J Surg Oncol. 2019;17:141.
- [15] Wu J, Ye T, Lv J, et al. Laparoscopic nerve-sparing radical hysterectomy versus laparoscopic radical hysterectomy in cervical cancer: a systematic review and meta-analysis of clinical efficacy and bladder dysfunction. J Minim Invasive Gynecol. 2019;26:417–426.e6.
- [16] Yuan Z, Cao D, Yang J, et al. Laparoscopic versus open abdominal radical hysterectomy for cervical cancer: a single-institution, propensity score matching study in China. Front Oncol. 2019;9:1107.
- [17] Mengatto MF, Castro BGR, Nobrega L, et al. Early removal of indwelling urinary catheter after radical surgery for early-stage cervical cancer-A cohort study. J Surg Oncol. 2020;122:1498–505.
- [18] Zhang YN, Li B, Wang YT, et al. [Efficacy and safety of laparoscopic radical hysterectomy for early cervical adenocarcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2020;55:600–8.

- [19] Ceccaroni M, Roviglione G, Malzoni M, et al. Total laparoscopic versus conventional open abdominal nerve-sparing radical hysterectomy: clinical, surgical, oncological and functional outcomes in 301 patients with cervical cancer. J Gynecol Oncol. 2021;32:e10.
- [20] Zong J, You M, Li C. Effect of Kegel Pelvic floor muscle exercise combined with clean intermittent self-catheterization on urinary retention after radical hysterectomy for cervical cancer. Pak J Med Sci. 2022;38:462–8.
- [21] Nezhat F, Mahdavi A, Nagarsheth NP. Total laparoscopic radical hysterectomy and pelvic lymphadenectomy using harmonic shears. J Minim Invasive Gynecol. 2006;13:20–5.
- [22] Tseng CJ, Shen HP, Lin YH, et al. A prospective study of nerve-sparing radical hysterectomy for uterine cervical carcinoma in Taiwan. Taiwan J Obstet Gynecol. 2012;51:55–9.
- [23] Uccella S, Laterza R, Ciravolo G, et al. A comparison of urinary complications following total laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy to open abdominal surgery. Gynecol Oncol. 2007;107:S147–9.
- [24] Wenzel HHB, Kruitwagen R, Nijman HW, et al. Short-term surgical complications after radical hysterectomy-A nationwide cohort study. Acta Obstet Gynecol Scand. 2020;99:925–32.
- [25] Wu K, Zhang WH, Zhang R, et al. [Analysis of postoperative complications of radical hysterectomy for 219 cervical cancer patients]. Zhonghua zhong liu za zhi. 2006;28:316–9.
- [26] Yan X, Li G, Shang H, et al. Complications of laparoscopic radical hysterectomy and pelvic lymphadenectomy--experience of 117 patients. Int J Gynecol Cancer. 2009;19:963–7.